Abstract
Dinaciclib enhances NK-cell activity against leukemia cells in preclinical AML models.
Enhanced NK-cell activation by dinaciclib-treated AML is associated with downregulation of inhibitory NK ligand HLA-E on leukemia cells.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Biomarkers
-
Bridged Bicyclo Compounds, Heterocyclic / pharmacology*
-
Bridged Bicyclo Compounds, Heterocyclic / therapeutic use
-
Cell Line, Tumor
-
Cyclic N-Oxides
-
Cytotoxicity, Immunologic / drug effects*
-
Disease Models, Animal
-
Humans
-
Immunomodulation / drug effects*
-
Immunophenotyping
-
Indolizines
-
Killer Cells, Natural / drug effects*
-
Killer Cells, Natural / immunology*
-
Killer Cells, Natural / metabolism
-
Leukemia, Myeloid, Acute / drug therapy
-
Leukemia, Myeloid, Acute / immunology*
-
Leukemia, Myeloid, Acute / metabolism
-
Lymphocyte Activation / drug effects
-
Lymphocyte Activation / immunology
-
Mice
-
Protein Kinase Inhibitors / pharmacology*
-
Protein Kinase Inhibitors / therapeutic use
-
Pyridinium Compounds / pharmacology*
-
Pyridinium Compounds / therapeutic use
-
Xenograft Model Antitumor Assays
Substances
-
Biomarkers
-
Bridged Bicyclo Compounds, Heterocyclic
-
Cyclic N-Oxides
-
Indolizines
-
Protein Kinase Inhibitors
-
Pyridinium Compounds
-
dinaciclib